BIIB

SEC source: 0001127602-19-007261 · form4.xml · derivative · entry 4

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,128

Underlying: Common Stock · 808 shares

Expires 2020-02-15

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-007261 · form4.xml · derivative · entry 3

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,936

Underlying: Common Stock · 1,318 shares

Expires 2020-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-007261 · form4.xml · nonDerivative · entry 2

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,485.1941

SEC source: 0001127602-19-007261 · form4.xml · nonDerivative · entry 1

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,071.1941

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-007260 · form4.xml · derivative · entry 4

McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,338

Underlying: Common Stock · 888 shares

Expires 2020-02-15

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-007260 · form4.xml · derivative · entry 3

McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,226

Underlying: Common Stock · 1,448 shares

Expires 2020-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-007260 · form4.xml · nonDerivative · entry 2

McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,324.631

SEC source: 0001127602-19-007260 · form4.xml · nonDerivative · entry 1

McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,967.631

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-007251 · form4.xml · derivative · entry 4

Ehlers Michael D · CIK 0001674364 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,724

Underlying: Common Stock · 1,033 shares

Expires 2020-02-15

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-007251 · form4.xml · derivative · entry 3

Ehlers Michael D · CIK 0001674364 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,757

Underlying: Common Stock · 1,685 shares

Expires 2020-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-007251 · form4.xml · nonDerivative · entry 2

Ehlers Michael D · CIK 0001674364 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,777.171

SEC source: 0001127602-19-007251 · form4.xml · nonDerivative · entry 1

Ehlers Michael D · CIK 0001674364 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,526.171

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-007250 · form4.xml · derivative · entry 4

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,724

Underlying: Common Stock · 1,033 shares

Expires 2020-02-15

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-007250 · form4.xml · derivative · entry 3

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,757

Underlying: Common Stock · 1,685 shares

Expires 2020-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-007250 · form4.xml · nonDerivative · entry 2

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,027

SEC source: 0001127602-19-007250 · form4.xml · nonDerivative · entry 1

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,776

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-006317 · form4.xml · nonDerivative · entry 1

Posner Brian S · CIK 0001372455 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,895

SEC source: 0001127602-19-006101 · form4.xml · derivative · entry 5

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,570

Underlying: Common Stock · 37,570 shares

Expires 2022-02-12

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006101 · form4.xml · derivative · entry 4

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,216

Underlying: Common Stock · 5,205 shares

Expires 2021-02-12

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006101 · form4.xml · derivative · entry 3

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,421

Underlying: Common Stock · 6,899 shares

Expires 2021-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006101 · form4.xml · nonDerivative · entry 2

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,645.27

SEC source: 0001127602-19-006101 · form4.xml · nonDerivative · entry 1

Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,267.27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-006099 · form4.xml · derivative · entry 13

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,528

Underlying: Common Stock · 1,188 shares

Expires 2021-02-12

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006099 · form4.xml · derivative · entry 12

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,716

Underlying: Common Stock · 1,574 shares

Expires 2021-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006099 · form4.xml · derivative · entry 11

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,453 shares

Expires 2019-02-12

F5 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest each year for four years, beginning two years from the date of grant. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-006099 · form4.xml · derivative · entry 10

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,453

Underlying: Common Stock · 1,965 shares

Expires 2019-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest each year for four years, beginning two years from the date of grant. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

SEC source: 0001127602-19-006099 · form4.xml · derivative · entry 9

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,211

Underlying: Common Stock · 1,104 shares

Expires 2020-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date.

SEC source: 0001127602-19-006099 · form4.xml · derivative · entry 8

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,330

Underlying: Common Stock · 10,330 shares

Expires 2022-02-12

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 7

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,753.1941

SEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 6

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,452.1941

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 5

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,878.1941

SEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 4

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,751.1941

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 3

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,786.1941

SEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 2

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,374.1941

SEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 1

Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,732.1941

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 74.812 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2018.

SEC source: 0001127602-19-006086 · form4.xml · derivative · entry 1

Kramer Robin · CIK 0001609222 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 860

Underlying: Common Stock · 860 shares

Expires 2022-02-12

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006088 · form4.xml · derivative · entry 8

McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,960

Underlying: Common Stock · 10,960 shares

Expires 2022-02-12

F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006088 · form4.xml · derivative · entry 7

McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,314

Underlying: Common Stock · 1,357 shares

Expires 2021-02-12

F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006088 · form4.xml · derivative · entry 6

McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,671

Underlying: Common Stock · 1,799 shares

Expires 2021-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006088 · form4.xml · derivative · entry 5

McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,527

Underlying: Common Stock · 1,263 shares

Expires 2020-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date.

SEC source: 0001127602-19-006088 · form4.xml · nonDerivative · entry 4

McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,519.631

SEC source: 0001127602-19-006088 · form4.xml · nonDerivative · entry 3

McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,058.631

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-006088 · form4.xml · nonDerivative · entry 2

McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,259.631

SEC source: 0001127602-19-006088 · form4.xml · nonDerivative · entry 1

McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,639.631

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 74.812 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2018.

SEC source: 0001127602-19-006084 · form4.xml · derivative · entry 1

Karp Daniel · CIK 0001744046 · EVP, Corporate Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,260

Underlying: Common Stock · 6,260 shares

Expires 2022-02-12

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006082 · form4.xml · derivative · entry 1

Guindo Chirfi · CIK 0001722753 · EVP Glob. Mkt Acc & Cust Innov

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,960

Underlying: Common Stock · 10,960 shares

Expires 2022-02-12

F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006080 · form4.xml · derivative · entry 8

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,890

Underlying: Common Stock · 6,890 shares

Expires 2022-02-12

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006080 · form4.xml · derivative · entry 7

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,788

Underlying: Common Stock · 814 shares

Expires 2021-02-12

F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006080 · form4.xml · derivative · entry 6

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,602

Underlying: Common Stock · 1,078 shares

Expires 2021-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-19-006080 · form4.xml · derivative · entry 5

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,517

Underlying: Common Stock · 758 shares

Expires 2020-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date.